RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Inclacumab was generally well tolerated in THRIVE-131
Phase 1 dosing is expected to finish by the end of 2025
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Subscribe To Our Newsletter & Stay Updated
